Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may predict who will respond to psychosis treatment

NCT ID NCT02670447

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether MRI brain scans can help predict which patients having their first psychotic episode will not respond to standard treatment. Researchers will scan 80 people aged 18-35 with schizophrenia or related disorders who have never taken antipsychotic medication. The goal is to see if certain brain markers can identify non-responders by the third month of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI (Magnetic Resonance Imaging)
What this could lead to
If successful, this could help doctors identify non-responding patients earlier, allowing for faster adjustments in treatment.
What could go wrong
This is a small, early-stage study (80 participants) focused on observation, not treatment. The MRI markers may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients suffering of schizophrenia will be included in this study. They do not have ever taken anti-psychotic treatment.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * men and women aged 18-35 years * member or beneficiary of a social security scheme, * for women, appropriate contraception will be mandatory, as well as a negative pregnancy test, * patients with a diagnosis of schizophrenia, schizoaffective disorder or schizophreniform disorder according to the DMS V * having never received anti-psychotic treatment, * followed in the hospital or outpatient, * having given their written informed consent, * that the physical examination revealed no significant clinical abnormalities Exclusion Criteria: * Female patients of childbearing period without effective contraception (oral, intramuscular hormonal, intrauterine device, or surgical); * Patients pregnant or nursing; * Presenting a serious somatic or neurological disease, especially Parkinson's disease, epilepsy, debilitating tardive dyskinesia, cardiovascular disease, severe liver or kidney; * Featuring against-indication for an MRI; including: metallic foreign body eye or intracranial, pacemaker, heart valve, surgical clips, claustrophobia, large tattoo in the upper part of the body, not compatible with 3T MRI * Having a history of alcohol or drug abuse in the past year; * Participating in another clinical trial or being in an exclusion period of the previous protocol; * Patients likely to exhibit aggressive behavior self according to the judgment of the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Clermont-Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63003, France

  • Chu Grenoble

    NOT_YET_RECRUITING

    Grenoble, 38000, France

  • Chu Le Vinatier

    NOT_YET_RECRUITING

    Bron, 69500, France

  • Chu Saint Etienne

    RECRUITING

    Saint-Etienne, 42100, France

  • HÔPITAL Edouard Herriot

    NOT_YET_RECRUITING

    Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.